Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET

29 Feb 2024

Abstract excerpt

Abstract The limited availability of molecularly targeted low‐molecular‐weight imaging agents for monitoring multiple myeloma (MM)‐targeted therapies has been a significant challenge in the field. In response, a first‐in‐class peptide‐based radiotracer, [68Ga]Ga‐AJ206, is developed that can be seamlessly integrated into the standard clinical workflow and is specifically designed to noninvasively quantify CD38...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced biosensing and bioanalysis techniques
Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38421139
DOI: 10.1002/advs.202308617

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PETPMID 38421139Read ↗

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read ↗

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumabSemantic proximity Read ↗

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Semantic proximity Read ↗

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabSemantic proximity Read ↗

Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple MyelomaSemantic proximity Read ↗

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaSemantic proximity Read ↗

Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against MyelomaSemantic proximity Read ↗

Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against MyelomaSemantic proximity Read ↗

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detectionSemantic proximity Read ↗

Targeted Alpha Therapy with [ <sup>225</sup> Ac]Ac-Macropa-Isatuximab for CD38-positive Hematological MalignanciesSemantic proximity Read ↗

Exploration of Bicyclic Peptide Ligands for Immune-Specific PET Imaging: Targeting Tumor PD-L1 with [18F]AlF-BCY10959Semantic proximity Read ↗

Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic MacrophagesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.